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Abstract Using model spontaneously reverting cell lines, c-jun,junB,junD and c-fos oncogene xpression was investigated. c-jun, but not junB, junD 
or c-fos, was overexpressed in highly tumorigenic lones. The reversion of cells to the non-tumorigenic phenotype resulted in a dramatic decrease 
in c-jun expression. CAT assays revealed that c-jun overexpression i tumorigenic ells was associated with higher transcription activity. No correlation 
between c-jun oncogene expression and AP-1 transcription factor activity in tumorigenic and non-tumorigenic lones was found. 
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1. Introduction 
A model of spontaneous tumor progression and reversion of 
cells to non-tumorigenic phenotype in vitro was previously 
described by Lavrovsky et al. [l]. In that study several inde- 
pendently transformed cell lines were isolated from embryonic 
fibroblasts of mice and rats with different genotypes. Highly 
tumorigenic cell variants, including metastatic ones, were se- 
lected in six cell lines. At the beginning of transformation, all 
cell lines were found to be non-tumorigenic, or only slightly so. 
At the same time, they demonstrated high sensitivity to the 
density-dependent inhibition of cell growth and possessed sen- 
sitivity to serum growth factors. During tumor progression, 
both properties changed dramatically. It is interesting to note 
that, in the process of cloning, four of six highly tumorigenic 
cell lines were shown to revert with high frequency to the 
non-tumorigenic state, possessing their initial growth charac- 
teristics. 
Additionally, the frequencies of reversion of cell lines were 
constant genetic characteristics of the cells. Surprisingly, re- 
verted cells could revert back to the highly tumorigenic pheno- 
type, although the frequencies of back reversions were much 
more rare. Thus, we have obtained several groups of tumo- 
rigenic clones which could interconvert. The mechanism of 
tumor cell transformation, and the mechanisms of reversion 
and back reversion, could have common motifs. Studies of this 
model may shed light not only on the process of tumor transfor- 
mation, but also on neoplastic non-stability mechanisms, which 
may be quite important for the prognosis of neoplasms. 
It is known that several of the immediate-early genes, such 
as members of the fos and jun families, encode transcription 
factors, and play an important role in the complex signals for 
growth and differentiation [2]. In the present report we show 
that C-~WZ, but not c-fos, junB or junD, is overexpressed in highly 
tumorigenic clones compared with its low expression in 
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Abbreviations: CAT, chloramphenicol acetyltransferase; FCS, fetal calf 
serum; AP-1, activator protein 1; TPA, 12-O-tetradecanoylphorbol-13- 
acetate. 
reverted ones and that such C-~WI overexpression is associated 
with higher transcription activity in tumorigenic clones. 
2. Materials and methods 
2.1. Cell cultures 
FCBA2VlO (clone 1) and non-tumorigenic revertant (clone 23). as 
well as tumorigenic FC3H3V7 (clone 29) and non-tumorigenic rever- 
tant (clone 20) were used [l]. The cell cultures were maintained in 
Eagle’s minimal essential medium (MEM) supplemented with 10% FCS 
in 5% CO, at 37°C. All cell cultures were found to be mycoplasma-free 
[I]. Retardation of growth of reverted clones was attained by cultivating 
cell monolayers for 2448 h in medium with 10% bovine adult serum. 
Stimulation of those cells was achieved by 20% FCS. 
2.2. RNA extraction and Northern blot analysis 
RNA extraction and Northern blot analysis were performed as de- 
scribed [3]. Blots were hybridized with the EcoRI-EcoRI cDNA frag- 
ment of the mouse c-jun, or junB, or junD (ATCC, MD; nos. 63026, 
63024,63025, respectively), as well as the 1 .O kb pair PstI-PstI fragment 
of v-fos (specific radioactivity 5 x 10’ cpm/pg). As a control, all filters 
were reprobed with cDNA encoding G3PDH (Clontech) to ensure that 
equal amounts of RNA were loaded onto each lane. 
2.3. Electrophoretic mobility shift assay (EMSA) 
Synthetic oligonucleotides corresponding to the TPA responsive le- 
ment (TRE) of the metallothioneine promoter region (5’-GATCCAT- 
GAGTCAGAG) were synthesized by a standard method [4]. The 
oligonucleotides were S-end-labelled using [y-“P]ATP and T4 polynu- 
cleotide kinase, and purified by polyacrylamide gel electrophoresis 
followed by reverse phase HPLC (SilasorbX8; O-50% gradient of ace- 
tonitrile with 20 mM LiCIO,). Nuclear protein extracts were prepared 
following the method of Digham et al. [5]. EMSA was performed as 
previously described [6]. 5 pg of nuclear protein and lo4 cpm of oligonu- 
cleotide with specific radioactivity lo6 cprn/,ug were taken per single 
reaction mixture. As a non-specific DNA-carrier, 2 pg of sonicated 
total DNA from bovine thymus were used. Control competition exper- 
iments included 50-fold molar excess of specific non-radiolabelled ol- 
igonucleotides. 
2.4. Transient transfection and CAT assay 
Plasmid jun-CAT was constructed by inserting the BamHI-SalI (2.4 
kb) fragment of the human c-jun promoter egion into the BamHI-XhoI 
sites of the tk-CAT plasmid instead of the TK promoter. Cells were 
transfected with 3 pg of plasmid DNA per flask, using a mammalian 
transfection kit (Stratagene, CA; no. 200388). Cells were incubated with 
the DNA coprecipitate for 4 h in media without serum in 3% CO, at 
37”C, washed with PBS, pH 7.4, and further incubated in DMEM 
containing 10% FCS for 24 h in 5% CO* at 37°C. Transfection 
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efficiency was monitored by transfection with the tk-CAT plasmid. 
CAT activity of the cell extracts was determined according to the 
method of Gorman et al. [A. 10 ,ug of the cellular protein, 0.1 mg of 
acetyl CoA and 5 ,Ki of [‘4C]chloramphenicol were used for each CAT 
assay. All experiments were performed at least 3 times. 
3. Results and discussion 
Fig. 1 shows the data concerning c-fos, c-jun, junB and junD 
mRNA content in two pairs of clones with CBA and C3H 
genotypes. c-fos mRNA was observed in both reverted clones 
only after 30 min stimulation of the quiescent cells with FCS 
(lanes 2 and 6, respectively). Neither logarithmic non-tumo- 
rigenic clones nor logarithmic tumorigenic ones showed any 
significant quantity of c-fos mRNA (lanes 3, 7 and 4, 8, respec- 
tively). These findings are in complete accordance with previ- 
ous data concerning c-fos regulation in normal and some tumo- 
rigenic cells [2,8,9]. junB mRNA was expressed in a manner 
similar to that of c-fos in both cell types, while junD mRNA was 
undetectable in all cell types . Most interestingly, c-jun mRNA 
levels were similar to c-fos mRNA levels only for reverted 
clones (Fig. 1, lanes l-3 and 5-7). In highly tumorigenic clones 
c-jun overexpression was observed (Fig. 1, lanes 4 and 8). 
Transient transfection experiments using the jun-CAT plas- 
mid were performed to analyze the transcription activity of the 
c-jun promoter in tumorigenic and non-tumorigenic cells. Cells 







Fig. 1. mRNA content of c-jun,junB,junD and c-for in tumorigenic and 
non-tumorigenic reverted cells of two genotypes (Northern hybridiza- 
tion assay). 10 pug of total RNA were loaded per lane. Equal loading 
of RNA per lane was monitored by hybridization with G3PDH cDNA. 
14 = FCBAZVlO cells; 5-8 = FC3H3V7 cells. (1 and 5) = quiescent 
reverted cells; (2 and 6) = quiescent reverted cells treated with 20% FCS 
for 30 min; (3 and 7) = reverted cells in logarithmic phase of growth; 
(4 and 8) = tumorigenic ells in logarithmic phase of growth. 
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Fig. 2. CAT assay in extracts from logarithmic phase FC3H3V7 cells 
transfected with jun-CAT and tk-CAT plasmids. (1) Non-tumorigenic 
reverted cells; (2) tumorigenic ells; (3) no extract. 
phase of growth). As seen in Fig. 2 (upper panel), the transcrip- 
tion activity of the c-jun promoter in tumorigenic cells was 
significantly higher (lane 2) than that in non-tumorigenic cells 
(lane 1). Transfection efficiency was about the same for both 
cell lines, as monitored by k-CAT plasmid transfection (Fig. 
2, lower panel). The c-jun promoter region contains binding 
sites for the transcription factors Sp-1, CTF, NF-jtin, AP-2 
[lO-121, and AP-1, which can positively autoregulate c-jun pro- 
tooncogene expression [13]. A high level of AP-1 transcription 
factor binding activity could be expected as a consequence of 
c-jun overexpression in tumorigenic clones. Our experiments 
using EMSA with AP-1 oligonucleotides eliminated the AP-1 
transcription factor as a possible cause or consequence of c-jun 
overexpression because the activity of this transcription factor 
was equal in both tumorigenic and non-tumorigenic cells in the 
logarithmic phase of growth (Fig. 3A and B, lanes 3 and 4). The 
quiescent non-tumorigenic cells showed almost undetectable 
levels of AP-1 binding activity even after stimulation with 20% 
FCS for 30 min (Fig. 3A and B, lanes 1 and 2). The binding 
specificity was confirmed by competition experiments using 
unlabeled AP-1 oligonucleotide (Fig. 3, lane 5). Studies of other 
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Fig. 3. Electrophoretic mobility shift assay of TRE oligonucleotide with nuclear extract from FC3H3V7 (A) and FCBAZVlO (B) cells. (1) Quiescent 
reverted cells; (2) quiescent reverted cells stimulated with 20% FCS; (3) reverted cells in logarithmic phase of growth; (4) tumorigenic cells in 
logarithmic phase of growth; (5) the same as lane (4) plus 50-fold excess of specific ompetitor DNA. 
transcription factors which might be involved in c-jun overex- 
pression in tumorigenic cells or c-jun down-expression in pseu- 
donormal cells are in progress. 
Negative regulators of JUN, such as IP-1 [14] and Jif-1 [15], 
have been shown to decrease transformation by JUN. A dom- 
inant negative JUN mutant has also been shown to suppress 
in vivo tumor formation [16]. However, the exact role that the 
jun protein family plays in mediating reversion of of highly 
tumorigenic cell lines to non-tumorigenic phenotype remains to 
be determined. 
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